



Clinical trial results: Efficacy of BIC/F/TAF versus standard of care in the treatment of new HIV infection diagnoses in the context of 'test and treat'

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2019-003208-11 |
| Trial protocol | GB |
| Global end of trial date | 31 July 2023 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 12 March 2025 |
| First version publication date | 12 March 2025 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | CRF002 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------------------------------------------------------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04653194 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | IRAS: 271361, EudraCT: 2019-003208-11, REC Reference : 19/LO/1953 |

Notes:

Sponsors

| | |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Sponsor organisation name | Chelsea and Westminster Hospital NHS Foundation Trust |
| Sponsor organisation address | Unit G3, Harbour Yard, Chelsea Harbour, London, United Kingdom, SW10 0XD |
| Public contact | CI: Marta Boffito / marta.boffito@nhs.net, Chelsea and Westminster Hospital NHS Foundation Trust, 0044 02033156685, marta.boffito@nhs.net |
| Scientific contact | CI: Marta Boffito / marta.boffito@nhs.net, Chelsea and Westminster Hospital NHS Foundation Trust, 0044 02033156685, marta.boffito@nhs.net |

Notes:

Paediatric regulatory details

| | |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|------------------------------------------------------|----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 26 August 2024 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 26 June 2023 |
| Global end of trial reached? | Yes |
| Global end of trial date | 31 July 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to compare virological response in newly diagnosed HIV patients at week 12 when administering TAF/FTC/BIC (Biktarvy) versus TAF/FTC/DRV/c (Symtuza) in the context of 'test and treat'.

Protection of trial subjects:

Thorough informed consent process where the participant is made aware of study in detail risk benefits and given opportunity to answer any questions.

The possibility to withdraw the trial at any point.

Review of medical history and physical exam and other parameters as part of baseline visits to ensure participant is eligible and fit for the the study.

Data protection parameters to ensure the patient data is de-identified and only those who should have the access to the data.

Background therapy: -

Evidence for comparator: -

| | |
|-----------------------------------------------------------|---------------|
| Actual start date of recruitment | 30 March 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United Kingdom: 36 |
| Worldwide total number of subjects | 36 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|-------------------------------------------|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 36 |

| | |
|---------------------|---|
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Start of recruitment: 30/07/2020

End of recruitment : 31/07/2022

Study Finished follow up: 30/07/2023

Pre-assignment

Screening details: -

Pre-assignment period milestones

| | |
|----------------------------|----|
| Number of subjects started | 36 |
|----------------------------|----|

| | |
|------------------------------|----|
| Number of subjects completed | 36 |
|------------------------------|----|

Period 1

| | |
|----------------|------------------------------------------------------------|
| Period 1 title | Study Visits (week 1 to week 48 & EOS vi (overall period)) |
|----------------|------------------------------------------------------------|

| | |
|------------------------------|-----|
| Is this the baseline period? | Yes |
|------------------------------|-----|

| | |
|-------------------|-------------------------|
| Allocation method | Randomised - controlled |
|-------------------|-------------------------|

| | |
|---------------|-------------|
| Blinding used | Not blinded |
|---------------|-------------|

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|-------|
| Arm title | Arm 1 |
|------------------|-------|

Arm description:

Product: Biktarvy (B)

Dose: one tablet

Frequency: OD

| | |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

| | |
|----------------------------------------|----------|
| Investigational medicinal product name | Biktarvy |
|----------------------------------------|----------|

| | |
|----------------------------------------|--|
| Investigational medicinal product code | |
|----------------------------------------|--|

| | |
|------------|--|
| Other name | |
|------------|--|

| | |
|----------------------|--------|
| Pharmaceutical forms | Tablet |
|----------------------|--------|

| | |
|--------------------------|----------|
| Routes of administration | Oral use |
|--------------------------|----------|

Dosage and administration details:

50 mg/200 mg/25 mg film-coated tablets

1 table

OD

| | |
|------------------|-------|
| Arm title | Arm 2 |
|------------------|-------|

Arm description:

Product: Symtuza (S)

Dose: one tablet

Frequency: OD

| | |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

| | |
|----------------------------------------|---------|
| Investigational medicinal product name | Symtuza |
|----------------------------------------|---------|

| | |
|----------------------------------------|--|
| Investigational medicinal product code | |
|----------------------------------------|--|

| | |
|------------|--|
| Other name | |
|------------|--|

| | |
|----------------------|--------|
| Pharmaceutical forms | Tablet |
|----------------------|--------|

| | |
|--------------------------|----------|
| Routes of administration | Oral use |
|--------------------------|----------|

Dosage and administration details:

800 mg/150 mg/200 mg/10 mg film coated tablets

1 tablet

OD

| Number of subjects in period 1 | Arm 1 | Arm 2 |
|---------------------------------------|-------|-------|
| Started | 19 | 17 |
| Completed | 17 | 13 |
| Not completed | 2 | 4 |
| Lost to follow-up | 1 | 4 |
| Moved to different country | 1 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|------------------------------------------|
| Reporting group title | Study Visits (week 1 to week 48 & EOS vi |
|-----------------------|------------------------------------------|

Reporting group description: -

| Reporting group values | Study Visits (week 1 to week 48 & EOS vi | Total | |
|----------------------------------------------------|------------------------------------------|-------|--|
| Number of subjects | 36 | 36 | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 36 | 36 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Gender categorical Units: Subjects | | | |
| Female | 2 | 2 | |
| Male | 34 | 34 | |

End points

End points reporting groups

| | |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Reporting group title | Arm 1 |
| Reporting group description: | |
| Product: Biktarvy (B) | |
| Dose: one tablet | |
| Frequency: OD | |
| Reporting group title | Arm 2 |
| Reporting group description: | |
| Product: Symtuza (S) | |
| Dose: one tablet | |
| Frequency: OD | |
| Subject analysis set title | Primary Objective |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: | |
| Primary objective | Time weighted average change from baseline in log ₁₀ HIV RNA level recorded in viral load assays from initiation of treatment to week 12. |
| Secondary objectives | Absolute efficacy of study treatments: Proportion of patients treated with Biktarvy and Symtuza with HIV viral load less than 20 copies/ml and less than 50 copies/ml at week 2, 4, 12, 24, and 48 |

Primary: The primary endpoint is the virological response (HIV RNA<50copies/mL) at week 12 by time-weighted average change in log₁₀ HIV RNA recorded in viral load assays from treatment initiation to week 12, using two-sample Wilcoxon rank-sum test.

| | |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | The primary endpoint is the virological response (HIV RNA<50copies/mL) at week 12 by time-weighted average change in log ₁₀ HIV RNA recorded in viral load assays from treatment initiation to week 12, using two-sample Wilcoxon rank-sum test. |
| End point description: | The time-weighted mean decrease in log ₁₀ HIV RNA from treatment initiation to week 12 was significantly greater in B in comparison to D (3.1 vs. 2.6 log ₁₀ copies/mL, p<0.001). |
| End point type | Primary |
| End point timeframe: | |
| Baseline to 12 weeks | |

| End point values | Arm 1 | Arm 2 | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: small decimals | 19 | 17 | | |

Statistical analyses

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| Statistical analysis title | Two-sample, Wilcoxon rank-sum test. |
| Statistical analysis description: | |
| The primary endpoint is the virological response (HIV RNA<50copies/mL) at week 12 by time-weighted average change in log ₁₀ HIV RNA recorded in viral load assays from treatment initiation to week 12, | |

using two-sample Wilcoxon rank-sum test.

| | |
|-----------------------------------------|-------------------------------------|
| Comparison groups | Arm 1 v Arm 2 |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| P-value | < 0.001 ^[1] |
| Method | two-sample, Wilcoxon rank-sum test. |

Notes:

[1] - The time-weighted mean decrease in log₁₀ HIV RNA from treatment initiation to week 12 was significantly greater in B in comparison to D (3.1 vs. 2.6 log₁₀ copies/mL, p<0.001).

Adverse events

Adverse events information

Timeframe for reporting adverse events:

30 July 2020 to 31 July 2023

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|-----|
| Dictionary version | 5.0 |
|--------------------|-----|

Reporting groups

| | |
|-----------------------|----------|
| Reporting group title | Biktarvy |
|-----------------------|----------|

Reporting group description: -

| | |
|-----------------------|---------|
| Reporting group title | Symtuza |
|-----------------------|---------|

Reporting group description: -

| Serious adverse events | Biktarvy | Symtuza | |
|---------------------------------------------------|----------------|----------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 1 / 17 (5.88%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Dressler's syndrome | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Latent Tuberculosis | | | |
| Additional description: n | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Biktarvy | Symtuza | |
|-------------------------------------------------------|-------------------|------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 19 / 19 (100.00%) | 15 / 17 (88.24%) | |
| Vascular disorders | | | |

| | | | |
|------------------------------------------------------|-----------------|----------------|--|
| AAA | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Surgical and medical procedures | | | |
| Bichectomy | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Circumcision | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Neck liposuction | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Pacemaker insertion | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Root canal left upper molar | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Root canal repair | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Surgery on left testicle for mass extraction | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| General disorders and administration site conditions | | | |
| fatigue | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 1 / 17 (5.88%) | |
| occurrences (all) | 1 | 1 | |
| Fever | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | 0 / 17 (0.00%) | |
| occurrences (all) | 4 | 0 | |
| Reproductive system and breast disorders | | | |
| Purple plaque lesion on neck of penis | | | |

| | | | |
|--------------------------------------------------|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 3 / 19 (15.79%) | 2 / 17 (11.76%) | |
| occurrences (all) | 3 | 2 | |
| Pharyngeal mucus | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Phlegm | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Shortness of breath | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Sore throat | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 1 / 17 (5.88%) | |
| occurrences (all) | 1 | 1 | |
| Psychiatric disorders | | | |
| vivid dreams | | | |
| subjects affected / exposed | 3 / 19 (15.79%) | 1 / 17 (5.88%) | |
| occurrences (all) | 3 | 1 | |
| Anxiety | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | 1 / 17 (5.88%) | |
| occurrences (all) | 2 | 1 | |
| Depression | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 1 / 17 (5.88%) | |
| occurrences (all) | 1 | 1 | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Worsening of insomnia | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nightmares | | | |

| | | | |
|----------------------------------------------------------------------------------|----------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Sleep disturbance subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 2 | 1 / 17 (5.88%) 1 | |
| Suicidal ideation subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Investigations | | | |
| Colonoscopy subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Creatinine increased subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Endoscopy subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Low neutrophils subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Weight gain of more than 10% subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Weight loss subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Injury, poisoning and procedural complications | | | |
| Heatstroke subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Squirrel bite subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Nervous system disorders | | | |

| | | | |
|-----------------------------------------------------------------------------------|----------------------|----------------------|--|
| Dizziness subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 1 / 17 (5.88%) 1 | |
| Facialis on right side subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Headache subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 2 / 17 (11.76%) 2 | |
| Memory impaired subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Somnolence subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Blood and lymphatic system disorders | | | |
| Neutropenia subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 3 / 17 (17.65%) 3 | |
| Swollen neck lymph nodes subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Eye disorders | | | |
| Irritated eyes subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Keratoconus subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Sore left eye / blurry vision subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 2 | 0 / 17 (0.00%) 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 2 | 0 / 17 (0.00%) 0 | |
| Abdominal ultrasound | | | |

| | | |
|-----------------------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 |
| Acid reflux | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 |
| Constipation | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 1 / 17 (5.88%) |
| occurrences (all) | 1 | 1 |
| Diarrhoea | | |
| subjects affected / exposed | 3 / 19 (15.79%) | 2 / 17 (11.76%) |
| occurrences (all) | 3 | 2 |
| Gastritis | | |
| subjects affected / exposed | 4 / 19 (21.05%) | 0 / 17 (0.00%) |
| occurrences (all) | 4 | 0 |
| Gum lesion | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 |
| IBS/Gastritis | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 |
| Nausea | | |
| subjects affected / exposed | 2 / 19 (10.53%) | 2 / 17 (11.76%) |
| occurrences (all) | 3 | 2 |
| Nausea + vomiting | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 |
| Worsening of nausea | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 |
| Pruritus Ani | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 |
| stomach pain | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 |
| Vomiting | | |

| | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Hepatobiliary disorders Hepatic steanosis subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Skin and subcutaneous tissue disorders dry skin subjects affected / exposed occurrences (all) eczema on upper back subjects affected / exposed occurrences (all) Rash subjects affected / exposed occurrences (all) Night sweats subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 0 / 19 (0.00%) 0 4 / 19 (21.05%) 7 2 / 19 (10.53%) 2 | 0 / 17 (0.00%) 0 1 / 17 (5.88%) 1 4 / 17 (23.53%) 4 0 / 17 (0.00%) 0 | |
| Renal and urinary disorders Dysuria and penile discharge subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Musculoskeletal and connective tissue disorders Back Pain subjects affected / exposed occurrences (all) Left shoulder pain subjects affected / exposed occurrences (all) Muscular pain subjects affected / exposed occurrences (all) lower back pain subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 0 / 19 (0.00%) 0 0 / 19 (0.00%) 0 1 / 19 (5.26%) 1 | 1 / 17 (5.88%) 1 1 / 17 (5.88%) 1 1 / 17 (5.88%) 1 0 / 17 (0.00%) 0 | |

| | | | |
|-----------------------------------------------------------------------------------|----------------------|----------------------|--|
| Right hip/pelvic area pain subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Infections and infestations | | | |
| Athletes foot subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Chest infection subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 2 | 0 / 17 (0.00%) 0 | |
| Cold subjects affected / exposed occurrences (all) | 3 / 19 (15.79%) 3 | 2 / 17 (11.76%) 3 | |
| Cold sore subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Coryzal symptoms subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Covid-19 subjects affected / exposed occurrences (all) | 5 / 19 (26.32%) 6 | 2 / 17 (11.76%) 2 | |
| Early syphilis subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Folliculitis on back subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | 0 / 17 (0.00%) 0 | |
| Gonorrhoea subjects affected / exposed occurrences (all) | 4 / 19 (21.05%) 4 | 3 / 17 (17.65%) 3 | |
| Helicobacter pylori infection subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 17 (5.88%) 1 | |
| Hepatitis C | | | |

| | | | |
|------------------------------------|-----------------|----------------|--|
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Human papilloma virus infection | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Monkeypox | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Otitis media | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Rectal chlamydia | | | |
| subjects affected / exposed | 3 / 19 (15.79%) | 1 / 17 (5.88%) | |
| occurrences (all) | 3 | 1 | |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Syphilis | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| UTI | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Urine infection | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Vaginal thrush | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Metabolism and nutrition disorders | | | |
| Hyperlipidemia | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 02 March 2020 | <p>SA01 MHRA Notice of non-acceptance and response</p> <p>1. The exclusion criteria do not address all contraindications for both investigational medicinal products (IMPs). The protocol needs to be updated to exclude patients with any contraindication to either of the IMPs. The exclusion criterion has been revised to list all contraindications and the full list of contraindications have been added to the protocol as appendix 4 for reference.</p> <p>2. The statement in Section 4.4.3 of the protocol that investigators who opt to discontinue study drugs for an individual subject should discuss with the Chief Investigator prior to study drug discontinuation is not acceptable and needs to be removed. The statement has been removed as requested.</p> <p>3. The listed methods of contraception in Appendix 3 are acceptable for this protocol but are not highly effective methods with a failure rate of less than 1% per year as described in the Clinical Trial Facilitation Group document for clarification of effective contraception in clinical trials: http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf . Highly effective needs to be removed from the title of Appendix 3 and the first paragraph needs to describe acceptable methods rather than highly effective methods. In addition, the appendix titles and references should be corrected as Appendix 3 is described and referenced as "Sample collection, processing and shipping" in some sections of the protocol. 'Highly effective methods...' title revised to 'Acceptable methods for avoiding pregnancy in females of child bearing potential'. Statement about failure rates less than 1% removed. Sample collection, processing and shipping references have been removed from the protocol and replaced with 'refer to lab manual'.</p> <p>4. Section 4.4.1 of the protocol lists pregnancy as one of the reasons an investigator may discontinue study treatment.</p> |
| 13 April 2021 | SA02 Changes have been proposed in the protocol specifically in the update of the most recent SmPCs available for both the treatment arms. |
| 27 September 2021 | SA03 The primary reasons for this substantial amendment are as follows: <ul style="list-style-type: none"> • The section on safety information within the study protocol has been updated to bring it in line with the current approved SmPCs for the trial. • Extension to the planned recruitment and study end date (Last patient last visit) • Addition of a new PI • Modification to the PIS (Patient Information Sheet) to bring it in line with current approved SmPC for IMPs • Modification to the Informed Consent Form (ICF) to bring it in line with trial requirements • Supply chain verification of trial labelled stock • Specific risk assessment |
| 21 June 2022 | SA04 An annual update to the current approved SmPCs for the trial Syntuza SmPC dated 20 October 2021 Biktarvy SmPC dated 24 February 2022 <ul style="list-style-type: none"> • Change to the HIV viral load minimum detection from <20 copies to <50 copies in line with standard of care in the secondary endpoint section of the protocol. • Removal of the metabolomics laboratory details in the protocol. |
| 29 July 2022 | SA05 Site missed updated PIS from previews amendment (SA04). Annual updates to SmPC documents, which includes additional Special warnings and precautions for use, leading to changes to PIS which were not submitted as part of the SA 04 submission. Updated PIS forms will be submitted as part of this amendment to be reviewed. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/39244669>